Anteris Technologies Global Corp.

Listed Company

AVRCIK 0002011514NasdaqEmerging GrowthOrthopedic, Prosthetic & Surgical Appliances & SuppliesDelawareFY ends Dec 31

Period

FY 2025

Revenue

$1.91M

Net Income

$-94.14M

Total Assets

$23.00M

Equity

$-93.0K

Shares Out

97.23M

Op. Cash Flow

$-77.80M

Business

Anteris Technologies Global Corp. develops and commercializes transcatheter heart valve solutions for treatment of aortic stenosis and related structural heart conditions. It offers the DurAVR® transcatheter heart valve made from a single-piece ADAPT® anti-calcification bioscaffold and associated ComASUR® balloon-expandable delivery system, along with related research, development and clinical support services. The company organizes activities around product development and regulatory/clinical programs, manufacturing and commercialization efforts. It targets global TAVR markets, selling primarily to hospitals, heart valve centers, physicians and distributors across North America, Europe and other international markets.

Summary from filing dated 2025-03-12

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31
Net sales	2	3
Cost of products sold	−569,000	−1
Research and development expense	−69	−51
Selling, general and administrative expense	−26	−28
Operating loss	−94	−78
Other non-operating income, net	467,000	2
Interest and amortization of debt discount and expense	−73,000	−47,000
Net foreign exchange (losses)/gains	−744,000	1
Debt issuance costs	0	−465,000
Loss on debt extinguishment	0	−904,000
Fair value movement of derivatives	19,000	−61,000
Loss before income taxes from continuing operations	−94	−76
Income tax (expense)/benefit	0	0
Loss after income tax	−94	−76
Non-controlling interests	−81,000	324,000
Stockholders of the Company	−94	−76
Basic loss per share (in Dollars per share)	−2.55	−3.68
Diluted loss per share (in Dollars per share)	−2.55	−3.68

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Cash, cash equivalents and restricted cash	13	70	21
Accounts receivable from customers, net of allowances	32,000	208,000	—
Inventories	152,000	513,000	—
Prepaid expenses	642,000	640,000	—
Other current assets	2	3	—
Total Current Assets	16	75	—
Plant and equipment, net	5	5	—
Operating lease right-of-use assets, net	2	1	—
Intangible assets, net	65,000	189,000	—
Total Non-Current Assets	7	6	—
TOTAL ASSETS	23	81	—
Accounts payable	11	6	—
Accrued and other liabilities	10	10	—
Current portion of operating lease liabilities	566,000	747,000	—
Current portion of debt obligations	16,000	3,000	—
Total Current Liabilities	21	17	—
Operating lease liabilities	2	645,000	—
Long-term debt obligations	22,000	—	—
Other liabilities	177,000	812,000	—
Total Non-Current Liabilities	2	1	—
TOTAL LIABILITIES	23	18	—
COMMITMENTS AND CONTINGENCIES	—	—	—
Common Stock, $0.0001 par value, 400,000,000 shares authorized, 41,579,881 and 35,939,816 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	4,000	4,000	—
Preferred stock, $0.0001 par value, 40,000,000 shares authorized	0	0	—
Additional paid in capital	381	350	—
Accumulated other comprehensive loss	−10	−11	—
Accumulated deficit	−371	−276	—
TOTAL STOCKHOLDERS EQUITY	−93,000	63	—
Non-controlling interests	−160,000	−79,000	−403,000
TOTAL EQUITY (DEFICIT)	−253,000	63	19
TOTAL LIABILITIES AND EQUITY	23	81	—

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31
Depreciation and amortization expense	2	2
Equity-settled stock-based compensation	8	7
Debt issuance costs	0	465,000
Other items	−29,000	78,000
Accounts receivable, prepayments and other assets	−515,000	−911,000
Inventories	362,000	−71,000
Accounts payable, accrued and other liabilities	6	8
NET CASH USED IN OPERATING ACTIVITIES	−78	−61
Acquisition of plant and equipment	−2	−2
Acquisition of intangible assets	0	−14,000
Deferred proceeds from sale of distribution rights	1	0
NET CASH USED IN INVESTING ACTIVITIES	−596,000	−2
Net proceeds from share issues	26	120
Share issue transaction costs	−3	−4
Tax withholding paid on stock option exercises	−1	0
Proceeds from issuance of convertible notes	0	5
Repayment of debt	−1	−7
Debt issuance costs paid	0	−465,000
Cash settlement of contingent options on debt	0	−191,000
Principal payments on finance lease obligations	−14,000	−9,000
NET CASH PROVIDED BY FINANCING ACTIVITIES	21	113
Effect of exchange rate movements on cash, cash equivalents and restricted cash	−38,000	57,000
Net change during the year	−58	49
Cash received for research and development tax incentive	594,000	962,000
Operating cash outflows relating to operating leases	−969,000	−834,000
Non-cash additions to right-of-use assets and lease liabilities	2	295,000
Non-cash issue of shares/warrants to consultants for services provided	735,000	430,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro